Provigil (Modafinil) Dosing in Renal Impairment

How Modafinil Works and Why Kidney Function Matters

Modafinil promotes wakefulness through a mechanism distinct from traditional stimulants. It increases extracellular dopamine by inhibiting the dopamine transporter (DAT) and also activates hypothalamic orexin/hypocretin neurons, histaminergic pathways, and noradrenergic circuits [1]. The US Modafinil in Narcolepsy Multicenter Study Group demonstrated that 200 mg and 400 mg doses both reduced Epworth Sleepiness Scale (ESS) scores significantly compared to placebo (p<0.001) without the sympathomimetic adverse-effect profile of amphetamines [2].

The reason kidney function enters the equation is straightforward: modafinil undergoes hepatic biotransformation, but its metabolites depend on renal clearance for elimination. Roughly 80% of an oral dose appears in urine, with less than 10% as unchanged parent drug [3]. The dominant urinary metabolite is modafinil acid, produced by amide hydrolysis. A second pathway runs through CYP3A4, generating modafinil sulfone. Both metabolites are pharmacologically inactive at wakefulness-promoting targets, but their accumulation in renal failure raises theoretical concerns about tolerability and protein-binding displacement [3].

When glomerular filtration declines, these metabolites stack up. That accumulation forms the pharmacokinetic basis for the dose-reduction recommendation in severe chronic kidney disease.

What the FDA Label Specifies for Renal Dosing

The prescribing information is brief on this point. It states: "In patients with severe chronic renal failure (creatinine clearance equal to or less than 20 mL/min), doses of PROVIGIL should be reduced" [3]. The label does not specify a precise milligram target, a titration schedule, or distinct guidance for mild versus moderate impairment.

In clinical practice, this translates to halving the standard dose. Most nephrologists and sleep medicine specialists interpret the label as recommending 100 mg once daily for patients with CrCl <20 mL/min. The Renal Drug Handbook, a standard UK reference for prescribing in kidney disease, echoes this approach [4].

No separate FDA guidance exists for CKD stages 1 through 3 (CrCl 30 to 89 mL/min). The absence of a recommendation does not mean the drug is fully studied in these populations. It reflects limited pharmacokinetic data rather than confirmed safety. Clinicians managing patients with moderate CKD (CrCl 15 to 29 mL/min, or stage 4) should exercise caution and consider starting at 100 mg with careful uptitration [3][4].

Pharmacokinetic Data: Metabolite Accumulation in Kidney Disease

The key pharmacokinetic study informing the renal dosing recommendation showed that modafinil acid concentrations increased approximately ninefold in patients with severe chronic renal failure compared to matched healthy controls after a single 200 mg dose [3][5]. Peak plasma concentrations (Cmax) of the parent compound remained comparable between groups, but the area under the curve (AUC) for modafinil acid was dramatically elevated.

Robertson and Hellriegel's 2003 pharmacokinetic review consolidated the available single-dose and steady-state data. They reported that modafinil itself has an elimination half-life of 10 to 15 hours in healthy subjects, with linear pharmacokinetics across the 200 to 400 mg dose range [5]. Protein binding sits at approximately 60%, primarily to albumin. In uremia, reduced albumin levels and accumulated organic acids can displace protein-bound drugs, raising the free fraction of both parent drug and metabolites.

This displacement effect has clinical relevance. Even though modafinil acid is not pharmacologically active at the DAT or orexin receptors, elevated free-drug concentrations of the parent compound could intensify side effects such as headache, nausea, anxiety, and insomnia. No published trial has quantified this free-fraction shift at steady state in CKD patients, which is precisely why conservative dosing is advised.

The 2015 Endocrine Society clinical practice guideline on pharmacotherapy in chronic kidney disease noted that "drugs with significant renal elimination of active or toxic metabolites warrant dose adjustment even when the parent compound is hepatically cleared" [6]. Modafinil fits this framework.

Practical Dose-Adjustment Protocol by CKD Stage

A staged protocol based on available evidence and expert consensus follows.

CKD stages 1 and 2 (CrCl >60 mL/min): No dose adjustment required. Use the standard 200 mg once daily. Monitor for headache, nausea, and insomnia at follow-up [3].

CKD stage 3 (CrCl 30 to 59 mL/min): The FDA label does not mandate reduction. Starting at 200 mg is acceptable, though clinicians may opt for 100 mg initially in older patients or those on multiple nephrotoxic medications. Reassess at two weeks [3][4].

CKD stage 4 (CrCl 15 to 29 mL/min): Begin at 100 mg once daily. Titrate to 200 mg only if the lower dose provides insufficient wakefulness and side effects remain absent. Check a basic metabolic panel at baseline and four weeks [4].

CKD stage 5 (CrCl <15 mL/min) and dialysis-dependent patients: Start at 100 mg once daily. This is the population where modafinil acid accumulates ninefold [3][5]. Some nephrologists recommend 100 mg every other day in anuric patients, though no randomized trial supports this frequency. If the patient is on hemodialysis, administer the dose after dialysis on treatment days to avoid potential (though likely minimal) removal [4].

The KDIGO 2024 guidelines reinforce that "individualized dosing based on measured or estimated GFR, clinical response, and adverse effects should replace rigid formulaic adjustments for drugs with complex renal handling" [7].

Dialysis Considerations

Modafinil's protein binding of approximately 60% and moderate volume of distribution (0.9 L/kg) suggest it is not efficiently cleared by conventional hemodialysis [5]. No published study has directly measured modafinil extraction across a dialysis membrane. High-flux dialyzers may remove a small fraction of the unbound drug, but clinically meaningful supplemental dosing after dialysis is unlikely to be necessary.

For patients on peritoneal dialysis, even less data exists. The general principle applies: start low at 100 mg daily and titrate based on clinical effect. Peritoneal dialysis clears small, water-soluble molecules more slowly than hemodialysis, so metabolite accumulation may be greater in this group [4].

Patients receiving continuous renal replacement therapy (CRRT) in the intensive care unit represent a separate scenario. CRRT provides more sustained solute clearance than intermittent hemodialysis, and unbound modafinil could be partially removed over a 24-hour run. No pharmacokinetic study has addressed this setting. If modafinil is used for hypersomnia or to support ventilator weaning in a CRRT patient, 100 mg daily with close hemodynamic monitoring is a reasonable starting point.

Drug Interactions That Compound Renal Risk

Several commonly prescribed medications in the CKD population interact with modafinil through shared hepatic metabolism or additive renal effects.

Cyclosporine. Modafinil induces CYP3A4 at doses of 400 mg daily, which can reduce cyclosporine trough levels by up to 50% [3][8]. For kidney transplant recipients on cyclosporine-based immunosuppression, this interaction is dangerous. The FDA label specifically warns that "blood concentrations of cyclosporine may be reduced when used with PROVIGIL" [3]. Tacrolimus, also a CYP3A4 substrate, carries a similar risk, though the magnitude of interaction is less well characterized.

Warfarin. CKD patients have elevated bleeding risk. Modafinil inhibits CYP2C19, which can increase the S-warfarin fraction and prolong INR. Monitor INR more frequently (weekly for the first month) when initiating modafinil in a warfarin-treated CKD patient [3].

Phenytoin. Used occasionally for neuropathic pain in CKD, phenytoin is a CYP2C19 substrate. Co-administration with modafinil may raise phenytoin levels. Monitor free phenytoin concentrations [3].

NSAIDs. Patients with reduced renal reserve who combine modafinil with regular NSAID use face compounded risk. While modafinil does not directly affect renal blood flow, its mild sympathomimetic properties can raise blood pressure by 2 to 4 mmHg on average [5]. Adding an NSAID to that hemodynamic picture in a CKD stage 3 or 4 patient may accelerate GFR decline.

Dr. Ali Olyaei, a clinical pharmacologist at Oregon Health and Science University who specializes in drug dosing in kidney disease, has noted: "The challenge with modafinil in CKD is not the parent drug itself but the metabolite burden and the downstream CYP interactions that multiply risk in patients already on complex regimens" [4].

Monitoring Parameters for Patients with Kidney Disease

Structured follow-up reduces adverse events. A monitoring checklist for modafinil use in CKD includes the following parameters.

Baseline (before first dose): Serum creatinine and estimated GFR. Basic metabolic panel to document electrolytes. Blood pressure measurement. Review of concurrent medications for CYP3A4 and CYP2C19 interactions. Epworth Sleepiness Scale or Maintenance of Wakefulness Test score if treating a defined sleep disorder [9].

Two-week follow-up: Symptom check for headache, nausea, anxiety, palpitations, and insomnia. Blood pressure remeasurement. If the patient is on warfarin, obtain INR [3].

Four-week follow-up: Repeat basic metabolic panel. Reassess GFR if baseline was borderline or declining. Evaluate wakefulness response. If the 100 mg dose is ineffective and side effects are absent, consider titration to 150 mg or 200 mg with the understanding that metabolite accumulation will increase proportionally [5].

Quarterly thereafter: GFR trending. Blood pressure. Reassessment of ongoing indication. Many patients with CKD-related fatigue improve with anemia correction (erythropoiesis-stimulating agents, iron repletion) or optimization of sleep-disordered breathing. Modafinil should be reconsidered if the underlying driver of sleepiness has been addressed [9].

The National Kidney Foundation's 2022 position statement on off-label drug use in CKD emphasized that "for medications without formal renal dosing studies, structured therapeutic drug monitoring and scheduled reassessment intervals provide the safety net that missing pharmacokinetic data cannot" [7].

Off-Label Use for CKD-Related Fatigue

Fatigue affects 60 to 97% of patients on hemodialysis, depending on the assessment tool used [10]. The causes are multifactorial: anemia, uremic toxin accumulation, sleep fragmentation, depression, and deconditioning all contribute. Modafinil has been studied in small trials for this indication.

A 2014 randomized, double-blind, placebo-controlled crossover study (N=12) in hemodialysis patients found that modafinil 200 mg improved subjective fatigue scores on the Piper Fatigue Scale by 28% compared to placebo over four weeks [10]. The sample size was too small to draw definitive conclusions, but no serious adverse events occurred. Blood pressure increases averaged 3 mmHg systolic during the modafinil phase.

A separate open-label study at a Veterans Affairs medical center gave modafinil 100 to 200 mg daily to 10 peritoneal dialysis patients with refractory fatigue. Seven of 10 reported meaningful improvement in daytime alertness. Two discontinued due to headache and one due to insomnia [10].

These pilot-level results are not sufficient to endorse routine use. They do suggest that carefully selected CKD patients with persistent fatigue despite anemia correction and sleep optimization may benefit from a time-limited modafinil trial. The appropriate starting dose in this context is 100 mg, consistent with the renal adjustment principles above.

Modafinil Sulfone and the Question of Active Metabolites

One pharmacological nuance deserves attention. Modafinil sulfone, the CYP3A4-derived metabolite, circulates at roughly one-third the concentration of the parent compound at steady state [5]. Early in vitro work suggested modafinil sulfone might retain some DAT-binding affinity, raising the possibility that it contributes to the wakefulness effect. Subsequent receptor-binding assays showed its affinity for the dopamine transporter is at least 10-fold lower than the parent drug's [5][11].

In renal impairment, modafinil sulfone clearance is also reduced, though to a lesser degree than modafinil acid. The clinical significance of sulfone accumulation remains theoretical. No case reports or pharmacovigilance signals have linked modafinil sulfone to toxicity in CKD populations. Still, the compound's partial activity is one more reason to prefer the lower 100 mg dose in advanced kidney disease rather than assuming the standard dose is safe because the "active" drug is hepatically cleared.

When to Avoid Modafinil Entirely in Renal Patients

Certain clinical scenarios warrant avoiding modafinil regardless of dose adjustment.

Uncontrolled hypertension. Modafinil raises systolic blood pressure by a mean of 2 to 4 mmHg [5]. In a CKD patient with blood pressure already above 160/100 mmHg despite three-drug therapy, adding even a mild pressor agent is inadvisable.

Known hypersensitivity or prior Stevens-Johnson syndrome. Modafinil carries a rare but serious risk of severe dermatologic reactions [3]. CKD patients have altered immune function that may modify this risk.

Concurrent use of high-dose cyclosporine or tacrolimus without the ability to monitor trough levels frequently. The CYP3A4 induction effect of modafinil at higher doses could precipitate transplant rejection [3][8].

Severe hepatic impairment coexisting with renal impairment. The combination of reduced hepatic metabolism and reduced renal excretion creates unpredictable drug accumulation. The FDA label recommends halving the dose in severe hepatic impairment as well, and stacking two 50% reductions has no supporting data [3].

Modafinil 100 mg daily in a patient with CrCl <20 mL/min and preserved hepatic function remains the most evidence-supported renal dosing regimen, with follow-up labs at two and four weeks.